MGX
Price
$0.78
Change
-$0.07 (-8.24%)
Updated
Oct 16 closing price
Capitalization
43.07M
32 days until earnings call
Intraday BUY SELL Signals
OBIO
Price
$5.45
Change
-$0.29 (-5.05%)
Updated
Oct 16 closing price
Capitalization
354.02M
30 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MGX vs OBIO

MGX vs OBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MGX vs. OBIO commentary
Oct 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGX is a Hold and OBIO is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MGX with price predictions
Oct 16, 2026

Momentum Indicator for MGX turns negative, indicating new downward trend

MGX saw its Momentum Indicator move below the 0 level on September 15, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator turned negative. In 35 of the 39 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for MGX turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In 16 of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for MGX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGX advanced for three days, in 88 of 110 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

MGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.383) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (3.195) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. MGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for OBIO with price predictions
Oct 16, 2026

OBIO in -4.57% downward trend, sliding for three consecutive days on October 14, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OBIO declined for three days, in 190 of 242 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for OBIO moved out of overbought territory on September 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 18 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OBIO as a result. In 73 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

The Moving Average Convergence Divergence Histogram (MACD) for OBIO turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 30 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.

OBIO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where OBIO advanced for three days, in 162 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

OBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 132 of 181 cases where OBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.315) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (11.198) is also within normal values, averaging (437.542).

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
OBIO: Fundamental Ratings
OBIO
OUTLOOK RATING
1..100
84
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MGXOBIO
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
50%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
64%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
64%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 9 days ago
76%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
72%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
73%
COMPARISON
Comparison
Oct 17, 2026
Stock price -- (MGX: $0.78 vs. OBIO: $5.45)
Brand notoriety: MGX and OBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MGX: 89% vs. OBIO: 149%
Market capitalization -- MGX: $43.07M vs. OBIO: $354.02M
MGX [@Biotechnology] is valued at $43.07M. OBIO’s [@Biotechnology] market capitalization is $354.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MGX’s FA Score shows that 1 FA rating(s) are green while OBIO’s FA Score has 0 green FA rating(s).

  • MGX’s FA Score: 1 green, 4 red.
  • OBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, OBIO is a better buy in the long-term than MGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MGX’s TA Score shows that 4 TA indicator(s) are bullish while OBIO’s TA Score has 4 bullish TA indicator(s).

  • MGX’s TA Score: 4 bullish, 4 bearish.
  • OBIO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MGX is a better buy in the short-term than OBIO.

Price Growth

MGX (@Biotechnology) experienced а -21.60% price change this week, while OBIO (@Biotechnology) price change was -8.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.

Reported Earning Dates

MGX is expected to report earnings on Nov 18, 2026.

OBIO is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Biotechnology (-10.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
MGX
Daily Signal:
Gain/Loss:
OBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SH32.470.38
+1.18%
ProShares Short S&P500 (SH)
SPUT28.63-0.16
-0.56%
Innovator Daily PutWrite ETF (SPUT)
RSPE34.23-0.26
-0.77%
Invesco ESG S&P 500 Equal Weight ETF (RSPE)
QUAL224.93-1.79
-0.79%
iShares MSCI USA Quality Factor ETF (QUAL)
ESPO100.76-0.82
-0.81%
VanEck Video Gaming and eSports ETF (ESPO)

MGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGX has been loosely correlated with VYGR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if MGX jumps, then VYGR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGX
1D Price
Change %
MGX100%
-7.24%
VYGR - MGX
48%
Loosely correlated
-7.77%
EDIT - MGX
48%
Loosely correlated
-3.69%
SANA - MGX
43%
Loosely correlated
-8.28%
BCYC - MGX
42%
Loosely correlated
-3.89%
RXRX - MGX
42%
Loosely correlated
-16.71%
More